RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
On June 7, 2017, Radius Health, Inc. (the Company) held its
Annual Meeting of Stockholders (the Annual Meeting). A total
of38,047,773 shares of common stock were present in person or
represented by proxy at the Annual Meeting, representing
approximately 88% of the Companys outstanding common stock as of
April 12, 2017, the record date for the Annual Meeting. The
following are the voting results for the proposals considered and
voted upon at the Annual Meeting, all of which were described in
the Companys Definitive Proxy Statement filed with the U.S.
Securities and Exchange Commission on April 21, 2017 (the Proxy
Statement).
Proposal 1 The following nominees were elected as Class III
directors to serve on the Companys Board of Directors until the
2020 Annual Meeting of Stockholders, and until their respective
successors have been duly elected and qualified, based on the
following votes:
|
Nominee |
For |
Withheld |
Broker Non-Votes |
|
Willard H. Dere, M.D. |
29,308,867 |
4,354,813 |
4,384,093 |
|
Kurt C. Graves |
27,120,122 |
6,543,558 |
4,384,093 |
|
Anthony Rosenberg |
29,330,822 |
4,332,858 |
4,384,093 |
Proposal 2 The appointment of Ernst Young LLP as the Companys
independent registered public accounting firm for the year ending
December 31, 2017 was ratified, based on the following votes:
|
For |
Against |
Abstentions |
Broker Non-Votes |
|
37,646,504 |
394,492 |
6,777 |
Proposal 3 The compensation of the Companys named executive
officers as disclosed in the Proxy Statement was approved, on an
advisory basis, based on the following votes:
|
For |
Against |
Abstentions |
Broker Non-Votes |
|
31,220,534 |
2,428,182 |
14,964 |
4,384,093 |
About RADIUS HEALTH, INC. (NASDAQ:RDUS)
Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.